Capricor Q2 2024: $11M loss, positive FDA pre-BLA meeting, DMD trial fully enrolled

CAPRICOR THERAPEUTICS, INC.

2024-Q2 EPS reported -$0.66 revenue$8,878,315

Net loss $11.0M ($0.35/sh) in Q2 2024 vs $7.4M ($0.29) in Q2 2023; revenue $4.0M.
Cash $29.5M at June 30, 2024 (down from $39.5M at Dec 31); raised $2.1M via ATM at $6.46/sh.
Positive pre-BLA meeting with FDA for deramiocel; HOPE-3 Phase 3 fully enrolled (105 subjects).
Top-line data from HOPE-3 Cohort A expected Q4 2024; 3-year HOPE-2 OLE showed +3.7 point PUL benefit.
Cash runway into Q1 2025; added to Russell 2000/3000 indexes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.